Chardan Capital Upgrades CervoMed to Buy, Announces $14 Price Target

Benzinga · 4d ago
Chardan Capital analyst Daniil Gataulin upgrades CervoMed (NASDAQ:CRVO) from Neutral to Buy and announces $14 price target.